Cancers & treatments·Regimen libraryFirst line

Carboplatin + paclitaxel

Checked 2026-09-09

Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC

Also called CARBOPLATIN-TAXOL, Carboplatin-paclitaxel.

One cycle

every 21 days × 6 · about 18 weeks in total

21-day cycle × 6 (about 18 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Carboplatin Cytotoxic chemotherapy (platinum)	AUC 5-6	IV	D1
Paclitaxel Cytotoxic chemotherapy (taxane)	175 mg/m²	IV	D1

Cycles

21-day cycle

Emetogenicity

High (>90%)

G-CSF

Not routine

Notes

Carboplatin AUC 4 or above is classed as highly emetogenic by NCCN; three-drug prophylaxis including an NK1 antagonist.
RUBY: dostarlimab 500 mg every 3 weeks × 6 then 1,000 mg every 6 weeks up to 3 years. NRG-GY018: pembrolizumab 200 mg every 3 weeks × 6 then 400 mg every 6 weeks.

Used in

Ovarian cancer Endometrial cancer Cervical cancer Non-small-cell lung cancer

Trials

RUBY / ENGOT-EN6 / GOG-3031 NRG-GY018 / KEYNOTE-868 DUO-E / GOG-3041 / ENGOT-EN10

Products

CarboplatinPaclitaxel / nab-paclitaxel

Source

GOG-158 (Ozols), JCO 2003; NCCN Ovarian Cancer

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.